Welcome to our dedicated page for Neuraxis news (Ticker: NRXS), a resource for investors and traders seeking the latest updates and insights on Neuraxis stock.
NeurAxis, Inc. (NRXS) is a medical technology company listed on the NYSE American that focuses on neuromodulation therapies for chronic and debilitating conditions in children and adults. News about NeurAxis frequently centers on its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology and its IB-Stim device, which is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older.
Investors and clinicians following NRXS news can track developments in FDA 510(k) clearances, expanded indications, and clinical guideline recognition for PENFS-based therapies. Company announcements highlight milestones such as the first FDA clearance or approval for a treatment specifically addressing functional dyspepsia in adults, as well as inclusion of NeurAxis’s technology in leading academic society guidelines for pediatric functional abdominal pain in IBS.
NeurAxis news flow also covers reimbursement and coverage progress, including assignment and implementation of a Category I CPT code for PENFS procedures, new medical policy coverage decisions from commercial insurers, and a Veterans Affairs Federal Supply Schedule contract that lists IB-Stim as a drug-free treatment option. These updates provide insight into how payer coverage and coding infrastructure may affect access to PENFS therapies.
In addition, NRXS news includes financial results, capital markets activity, and corporate actions disclosed through earnings releases and Form 8-K filings. Topics include revenue trends from commercialization of IB-Stim, at-the-market equity offerings under a shelf registration statement, and adoption of an Employee Stock Purchase Plan. For a fuller picture of NeurAxis’s trajectory in neuromodulation, gastrointestinal indications, and reimbursement, readers can review this news feed regularly as new press releases and regulatory disclosures are issued.
NeurAxis (NYSE American: NRXS) reported strong Q2 2025 financial results, with revenues increasing 46% year-over-year to $894,000. The medical technology company, focused on neuromodulation therapies, achieved significant milestones including FDA clearance for expanded pediatric treatment and secured key academic society guidelines recommendation for their PENFS technology.
Operating expenses decreased 10% year-over-year, while operating loss improved by 22%. The company maintained a cash balance of $6 million, bolstered by a $5 million equity financing round. NeurAxis expanded its covered lives to 53 million and received a new Category I CPT code for PENFS procedures, effective January 2026. The company expects to achieve breakeven in 2026.
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions, has scheduled its Q2 2025 earnings call for Tuesday, August 12, 2025, at 9:00 AM ET. The financial results will be released before the market opens.
The company will host a live webcast accessible through their investor relations website, with options for participants to submit questions through the webcast portal or via email. A replay of the webcast will be available on the company's website following the call.
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025.
The company will deliver a webcast presentation at 9:30 a.m. ET and conduct one-on-one meetings with investors throughout the event. Interested parties can access the webcast through the conference website or directly via the provided link, with replay options available after the event.
NeurAxis (NYSE: NRXS) has successfully closed a registered direct offering of 1,538,461 shares of common stock at $3.25 per share, raising approximately $5.0 million in gross proceeds. The company also secured over $1 million from warrant exercises in the same week. This financing follows the recent FDA clearance expanding indications for IB-Stim treatment of Pediatric Functional Abdominal Pain (FAP). The company plans to implement a CPT Category I code effective January 1, 2026. Craig-Hallum Capital Group served as the exclusive placement agent for the offering, which was conducted under a shelf registration statement previously filed with the SEC.
NeurAxis (NYSE: NRXS), a medical technology company focused on neuromodulation therapies, has announced a $5.0 million registered direct offering of 1,538,461 common stock shares priced at $3.25 per share. The offering, expected to close around May 22, 2025, is being conducted through Craig-Hallum Capital Group as the exclusive placement agent.
The company plans to use the net proceeds for working capital and general corporate purposes. The offering is made under a shelf registration statement filed with the SEC in December 2024 and declared effective in February 2025.
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025. The company will release its financial results for the period ended March 31, 2025, before the market opens.
A conference call to discuss the results will be held the same day at 9:00 AM ET. Interested parties can access the call through a live webcast on the company's investor relations website or via dial-in registration. A replay will be available on the company's website following the call.